Welcome to our dedicated page for Neuphoria Therapeutics news (Ticker: NEUP), a resource for investors and traders seeking the latest updates and insights on Neuphoria Therapeutics stock.
Neuphoria Therapeutics Inc (NEUP) is a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders through advanced receptor modulation science. This page serves as the definitive source for verified news and official announcements related to their therapeutic pipeline, strategic partnerships, and clinical progress.
Investors and industry professionals will find timely updates on clinical trial milestones, regulatory developments, and financial disclosures. The curated collection includes press releases about their lead candidate BNC210 for anxiety disorders, research collaborations with major pharmaceutical partners, and scientific advancements in neuroscience.
All content undergoes strict verification to ensure accuracy and compliance with financial reporting standards. Users can expect regular updates covering key aspects of NEUP's operations including trial result announcements, intellectual property developments, and strategic business decisions that impact the neuropsychiatric treatment landscape.
Bookmark this page for direct access to primary source materials from Neuphoria Therapeutics, ensuring you stay informed about critical developments in this innovative biotech company's journey to address unmet mental health needs.
Neuphoria Therapeutics (NASDAQ: NEUP) has provided an update on its 2024 achievements and 2025 plans. The company reached significant milestones in its clinical programs, including:
The advancement of BNC210 to Phase 3 AFFIRM-1 trial for Social Anxiety Disorder (SAD), with topline results expected in Q3 2025. Additionally, Merck initiated a Phase 2 trial of MK-1167 for Alzheimer's disease treatment.
Key financial developments include receiving a US$15M milestone payment from Merck in March 2025, extending cash runway to Q3 2026. The company is eligible for up to $450M in additional milestone payments plus royalties from Merck, and AUS$117M from Carina Biotech for their partnered programs.
For 2025, Neuphoria plans to initiate a Phase 2b dose-ranging study of BNC210 in PTSD in Q4, following the SAD trial results. The company successfully re-domiciled from Australia to the United States in December 2024.
Neuphoria Therapeutics (Nasdaq: NEUP), a clinical-stage biotechnology company focused on neuropsychiatric disorder treatments, announced it will ring the Nasdaq Opening Bell on March 3rd, 2025, at the Nasdaq MarketSite in Times Square, New York City.
The ceremony will be led by President and CEO Spyros Papapetropoulos MD, PhD, accompanied by the company's board of directors, management team, and advisors. The event celebrates Neuphoria's successful redomiciliation to the US and the launch of Neuphoria Therapeutics. The live broadcast will begin at 9:15 a.m. Eastern Time.
Neuphoria Therapeutics (Nasdaq: NEUP) announced it will receive a $15 million milestone payment from Merck following the initiation of a Phase 2 clinical trial for MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator, in Alzheimer's disease dementia.
This marks the second milestone achieved in the Merck collaboration. Under the agreement, Neuphoria remains eligible for up to $450 million in additional milestone payments for development and commercial achievements, plus royalties on net sales of licensed medicines.
The Phase 2 trial (NCT06721156) will evaluate MK-1167's safety and efficacy in treating Alzheimer's disease symptoms. The milestone achievement validates Neuphoria's ion channel targeting platform, which has produced several clinical and preclinical stage drug candidates.
Neuphoria Therapeutics (Nasdaq: NEUP) has completed its re-domiciliation from Australia to the United States, transforming from Bionomics The company's shares will begin trading on Nasdaq under the symbol 'NEUP' starting December 24, 2024. As part of the transition, Neuphoria will issue new stock options to existing Bionomics option holders and a warrant to purchase 1,054,381 shares to an institutional investor who previously held warrants for 12,652,572 Bionomics American Depositary Shares (ADSs).
FAQ
What is the current stock price of Neuphoria Therapeutics (NEUP)?
What is the market cap of Neuphoria Therapeutics (NEUP)?
